Abstract
This paper explains that Bristol Meyers Squibb Corporation's (BMSC) primary strengths is its success at marketing its leading products in a highly competitive sector of the healthcare industry. The author points out that BMSC's performance in the marketplace is based on a thorough knowledge of its retail customers and its end consumer, which is obtained through marketing research. The paper describes the internal dimensions, such as perceptual filter, and external dimensions, such as culture, which influence consumer choice. The author underscores that the benefit of utilizing marketing research to identify these factors of consumer behavior is that BMSC can more appropriately formulate its market strategies The paper relates that the marketing plan applies resources to the identified consumer information to develop an effective marketing strategy.

Table of Contents
Overview
Influences
The Marketing Plan
Conclusion

From the Paper
"Part of the proper identification of a consumer need, particularly in the health care industry, is identifying the correct geographic areas within which the target consumers are primarily located. This is important for several reasons but primarily ensures that the proper market is reached, that the right product or service is placed before the consumer, and that duplication of services is avoided. These considerations are all requisite to the strategic planning process in conceiving the entire marketing plan, but particularly in delineating the correct geographic, and geo-demographic areas where the targeted consumers are physically located."

Tags:retail, geo-demographic, internal, external, strategy

Abstract
This paper presents an overview of the Bristol Meyers Squibb Corporation (BMSC), focusing on its successful marketing strategy. The paper further notes the company's marketing savvy, which has been effectively illustrated in previous analyses of the company which emphasizes BMSC's performance in the marketplace regarding its product, pricing, promotion, and distribution.

From the Paper
"Bristol Meyers Squibb Corporation (BMSC) has enjoyed a certain degree of success and has benefited from the troubles of one of its main rivals. In fact, success at marketing its leading products has been one of BMSC's primary strengths in this highly competitive sector of the healthcare industry. This marketing savvy, effectively illustrated in previous analyses of the company which emphasizes BMSC's performance in the marketplace regarding its product, pricing, promotion, and distribution..."

Tags:marketing, research, bristol

Abstract
This paper presents a marketing audit of Bristol Meyers Squibb Company (BMSC). First, the paper gives a general overview of the company. Then it describes how BMSC benefits from a series of partnerships and operating agreements that have greatly expanded its market.

From the Paper
"Bristol Myers Squibb Company's (BMSC) recent history can essentially be summed up by its battle with Pfizer to gain control of the cardiovascular drug market with its Pravachol, Plavix, and other cardiovascular related drugs. However, perhaps one of its greatest marketing mishaps in this regard was its failed test that resulted in boosting Pfizer's line of cardiovascular products; chiefly Pfizer's Lipitor: Pfizer has already proven Lipitor's superiority to Prevachol in cutting cholesterol, but its ability to improve mortality was untried, and..."

Tags:bristol, marketing, segment

Abstract
This paper discusses the pharmaceutical industry and the Bristol Myers Squibb Company (BMSC). It explores the internal and external forces within the pharmaceutical industry and BMSC's response to them are examined in detail. Additionally, the competitive forces within the industry are examined in relation to BMSC's strategic response to them. This is followed by a critical review of BMSC's strategic responses and their effectiveness. Finally, BMSC's corporate leadership and governance are discussed with some final observations on BMSC's corporate responsibility policies and organizations.

From the Paper
"This research document discusses the pharmaceutical industry and the Bristol Myers Squibb Company (BMSC). The internal and external forces within the pharmaceutical industry and BMSC's response to them are examined in detail. Additionally, the competitive forces within the industry are examined in relation to BMSC's strategic response to them. This is followed by a critical review of BMSC's strategic responses and their effectiveness. Finally, BMSC's corporate leadership and governance are discussed with some final observations on BMSC's corporate responsibility policies and organizations. Bristol Myers Squibb and the Pharmaceutical Industry Bristol Myers Squibb Overview Bristol Myers Squibb Company's (BMSC) recent history can essentially be summed up by its battle with Pfizer to gain control of the cardiovascular drug market with its Pravachol, Plavix, and other cardiovascular related drugs. However, perhaps one of its greatest marketing mishaps in this regard was its failed test that resulted in ..."

Tags:strategic, pharmaceutical, industry

Abstract
The paper reveals that Bristol Myers Squibb Company's (BMSC) recent history can be summed up by its battle with Pfizer to gain control of the cardiovascular drug market. The paper provides an overview of Pfizer and offers a competitor profile matrix. The paper then discusses the industry rivalry and includes a SWOT analysis. The paper concludes that BMSC has developed a very integrated manufacturing and distribution network that has allowed it to capitalize on its brand image as a leading pharmaceutical company. The paper provides recommendations and includes an appendix detailing the company's background.

Outline:
The Competitive Environment
BMSC in the Marketplace
Conclusions & Recommendations

From the Paper
"The degree of industry rivalry in the pharmaceutical industry is high and potentially debilitating even for the larger competitors. Proctor identifies five levels of competition that most enterprises face in today's hyper-competitive marketplace: direct, close, similar products, substitute products and indirect competition (2000, p.103). These levels of competition vector with Porter's five forces model of competition whereby he models the relationship in the marketplace between competitive forces that together form a core of rivalry that is measured in degrees of intensity (Proctor, 2000). For the pharmaceutical industry, the degree of intensity in competitive forces is extremely high because the risks at stake are considerable; often in the 100s of millions to the billions."

Tags:competition, Pfizer, drugs, strengths, weaknesses, opportunities, threats, segmentation

Abstract
This paper presents an overview of pharmaceutical company, Bristol Myers Squibb (BMSC) and then presents an environmental analysis of the pharmaceutical industry with regards to how BMSC can obtain a competitive edge. The paper presents a strengths, weaknesses, opportunities, and threats (SWOT) analysis of BMSC and discusses BMSC market segmentation. The paper concludes with recommendations for a marketing strategy.

Table of Contents:
BMSC Overview
The Competitive Environment
Pfizer Overview
Competitor Profile Matrix
Industry Rivalry
Environmental Analysis
BMSC SWOT
Strengths
Weaknesses
Opportunities
Threats
BMSC Segmentation
Conclusion and Recommendations
Conclusions
Recommendations
Appendix
Company Background
SWOT Table

From the Paper
"Pfizer had revenues of more than $52,000 million during 2004 which represented an increase of over 17% from the previous year. Pfizer's profit for 2004 was over $11,000 million which represented a year on year increase of over 300%. Financially Pfizer is a very strong company which markets pharmaceutical and consumer products in both human and animal markets concentrated in 3 segments: pharmaceuticals, consumer healthcare and animal healthcare. While continually investing in research and development, Pfizer is currently benefiting from 3 strong products in the marketplace: Viagra, Zoloft and Lipitor."

Tags:pfizer cardiovascular, delay and prosper strategy, integrated online, outsource

Abstract
The paper begins by looking at the products of Bristol-Myers Squibb and at the litigation against the company as a result of monopolizing the market. The government's policy on new entrants is discussed in terms of generics. It looks at industry competitors and product substitutes for medication. The paper concludes with a study of the suppliers of BMS and a look at who their customers are.

From the Paper
"Bristol-Myers Squibb is a major producer and distributor of medicines, nutritional products, and medical imaging equipment. They produce cardiovascular and metabolic medicines, mental health medicines; as well as headache, migraine, nervous system medicines. Some of their brands include: Excedrin Migraine over the counter medicine, and Enfamil infant formulas. They also produce Boost nutritional supplements and diabetic nutritional products.

Unfortunately, they also have some bad habits. For example, there were two anti-trust suits filed against them, for monopolizing the market in order to delay, or stop, the generic versions of the anti-cancer drug Taxol, and the anti-anxiety drug Buspar. The company was able to do this through manipulation of loopholes in the Hatch-Waxman Act. Under this act, brand name manufacturers list un-expired patents with the FDA in a listing, or compendium, known as the "Orange Book." This listing offers a reward of an automatic 30-month stay against certain potential generic entrants who have been sued for product infringement."

Tags:products, litigation, government, policy, entrants, generics, competitors, substitutes, suppliers, customers

Abstract
The paper relates that Bristol Myers Squibb Company's (BMSC) recent history can essentially be summed up by its battle with Pfizer to gain control of the cardiovascular drug market with its Pravachol, Plavix, and other cardiovascular related drugs. However, the paper discusses perhaps one of its greatest marketing mishaps in this regard that was its failed test that resulted in boosting Pfizer's line of cardiovascular products.

Tags:bristol, marketing, analysis

Abstract
This paper briefly examines Bristol-Myers Squibb's (BMS) entry into the market and discusses what new innocations this company has to offer the pharmaceutical industry. The paper then addresses the issue of market competition and discusses the different competitive players in the industry. It then explains product substitutes that BMS produces and concludes by mentioning its suppliers and buyers.

From the Paper
"Bristol-Myers Squibb is a major producer and distributor of medicines, nutritional products, and medical imaging equipment. They produce cardiovascular and metabolic medicines, mental health medicines; as well as headache, migraine, nervous system medicines. Some of their brands include: Excedrin Migraine over the counter medicine, and Enfamil infant formulas. They also produce Boost nutritional supplements and diabetic nutritional products."

Tags:medicine, natural, remedy, buyer, seller, market, competition, FDA

Abstract
Belo Corporation is a news information and content provider that operates primarily across the North and Southwest parts of the US. Its primary lines of business are television, newspapers, World Wide Web content, and cable news products. For the fiscal year that ended December 31, 2005, Belo recorded earnings in excess of $1.5 billion, which represented a very slight increase over the previous fiscal year. Belo operates 19 television stations which combine to reach an approximate 13.8% of the US viewing audience at any given period; it manages four daily newspapers of which the Dallas Morning News is the largest; and Belo operates just over 30 websites that combine total over 100 million hits a month. This paper examines Belo Corporation, looking at its lines of business, operations, earnings and management.

Tags:belo, corporation, management